Emergent BioSolutions reports Q2 adjusted EPS 16c vs ($2.32) last year

Reports Q2 revenue $140.9M vs $254.7M last year. “Our second quarter results exceeded the top end of our revenue guidance by $21 million, and the bottom line exceeded our own internal expectations. In light of this, we are raising the low end/midpoint of full year 2025 profitability guidance, reflecting strong execution of our multi-year transformation plan,” said Joe Papa, president and CEO of Emergent. “We are making solid progress against key turnaround priorities, driven by improved profitability, expanding margins and sustained positive cash flow. Year to date, we have secured seven biodefense contract modifications, further demonstrating our leadership in medical countermeasures with the U.S. government and allied government stakeholders. We continue to explore potential organic and inorganic opportunities and assess strategic external investments that support stable, long-term growth for the enterprise. With sustained demand for life-saving naloxone, NARCAN Nasal Spray 4 mg and KLOXXADO Nasal Spray 8 mg, as well as an encouraging outlook in our medical countermeasures business, we remain confident in our full year guidance and expect a strong second half of the year.”